AbbVie Inc.
CorpDigest
AbbVie Inc.
Company History
Founded 2013 in North Chicago, Illinois
Last reviewed: 2025-07-15 · By Swet Parvadiya
AbbVie Inc. is a Biopharmaceutical company with $56.3B in 2024 revenue and 50K employees worldwide. AbbVie Inc. Occupies a unique position in American business history as a company created specifically to extract maximum value from a single extraordinarily productive drug franchise, then forced to reinvent itself before that franchise's commercial dominance faded. The story of AbbVie is in many ways the story of modern biopharmaceutical capitalism: the identification of a breakthrough biological mechanism, the conversion of that mechanism into a commercial juggernaut through aggressive clinical development and marketing, the accumulation of profits sufficient to fund the next generation of innovation, and the execution — under extraordinary pressure — of a transition that most Wall Street analysts initially doubted. Headquartered in North Chicago, Illinois, roughly 35 miles north of downtown Chicago on a campus that sits within sight of Lake Michigan, AbbVie is deeply embedded in the broader Chicago-area business community. The company's executive leadership has remained relatively stable since the spin-off, with Richard Gonzalez serving continuously as Chairman and CEO — an unusual tenure by the revolving-door standards of large-cap pharmaceutical executives. This leadership continuity has allowed AbbVie to pursue a consistent long-term strategy even as quarterly financial results experienced significant volatility during the Humira biosimilar transition period. The company's employee base of approximately 50,000 spans scientific research functions in Lake County, Illinois, San Francisco's Bay Area, and other global innovation hubs; manufacturing operations across the United States, Ireland, Germany, and Singapore; and commercial operations in virtually every developed pharmaceutical market. This global footprint, built through a combination of organic growth and acquisition integration, gives AbbVie the operational capacity to commercialize new drugs across dozens of markets simultaneously — a capability that distinguishes large-cap pharmaceutical companies from the biotechnology startups that often make the initial scientific discoveries.
Richard A. Gonzalez was born and educated in the United States, earning a degree in science from the University of Houston. He joined Abbott Laboratories in 1977 and spent 35 years building expertise across pharmaceutical manufacturing, research operations, and commercial leadership before leading the spin-off that created AbbVie. As AbbVie's founding and continuing CEO, Gonzalez has presided over the company's entire history: the Humira peak, the Pharmacyclics acquisition, the Allergan mega-deal, the biosimilar transition, and the construction of the Skyrizi-Rinvoq platform. Under his leadership, AbbVie's market capitalization grew from approximately $54 billion at spin-off to over $320 billion by mid-2025. Gonzalez has been recognized repeatedly on Fortune's list of most powerful executives in business and has testified before Congress on pharmaceutical pricing policy. His tenure represents one of the longest continuous CEO runs of any large-cap pharmaceutical company in the contemporary era.
On January 1, 2013, AbbVie began trading independently on the NYSE under the ticker ABBV, inheriting Humira, a pharmaceutical research organization, and approximately 22,000 employees from Abbott Laboratories in one of the largest pharmaceutical spin-offs in U.S. History.
AbbVie announced and then withdrew its $54 billion proposed acquisition of Shire PLC following U.S. Treasury regulatory changes that eliminated most of the tax benefits of the inversion structure, resulting in a $1.6 billion break fee payment to Shire and a strategic reassessment of AbbVie's acquisition approach.
AbbVie acquired Pharmacyclics, the co-developer of blood cancer drug Imbruvica (ibrutinib), for approximately $21 billion, securing its share of Imbruvica's global profits and establishing a major oncology revenue stream alongside the immunology business built on Humira.
Humira achieved $16.1 billion in global net revenues in 2016, becoming the world's best-selling drug for the fourth consecutive year and demonstrating the commercial durability of the adalimumab franchise across an expanding range of inflammatory indications.
Biosimilar versions of adalimumab launched across multiple European markets in October 2018, triggering the first significant revenue erosion in Humira's commercial history and providing AbbVie with real-world data on biosimilar penetration dynamics that would inform its U.S. Transition planning.
The FDA approved risankizumab-rzaa (Skyrizi) for the treatment of moderate-to-severe plaque psoriasis in April 2019, marking the first major new product approval in AbbVie's immunology pipeline since Humira and the beginning of the next-generation immunology platform that would become central to the company's post-Humira strategy.
AbbVie completed the acquisition of Allergan plc in May 2020 for approximately $63 billion in cash and stock, the largest pharmaceutical acquisition of the year, adding Botox, Juvederm, and a global aesthetics portfolio alongside Allergan's prescription pharmaceutical assets in neurology and women's health.
Rinvoq (upadacitinib) received FDA approval expansions for atopic dermatitis and additional indications in 2021, validating AbbVie's investment in the JAK1 selective inhibitor platform despite the FDA's concurrent Black Box warning requirement for the entire JAK inhibitor drug class.
Humira achieved its all-time annual revenue peak of $21.2 billion in global net revenues in 2022, with U.S. Revenues of approximately $17.3 billion representing the final year before biosimilar competition fundamentally altered the drug's commercial trajectory.
Seven Humira biosimilars launched in the U.S. Market in January 2023, triggering significant Humira U.S. Revenue erosion while AbbVie's Skyrizi and Rinvoq revenues grew by over 50 percent combined, demonstrating the feasibility of the immunology franchise transition strategy.
AbbVie completed its $10.1 billion acquisition of ImmunoGen, bringing Elahere for platinum-resistant ovarian cancer into its oncology portfolio, and its $8.7 billion acquisition of Cerevel Therapeutics, adding the emraclidine schizophrenia program in Phase 3 development to its neuroscience pipeline.
AbbVie reported fiscal year 2024 net revenues of approximately $56.3 billion, with Skyrizi contributing approximately $10.9 billion and Rinvoq approximately $5.5 billion, confirming that the combined next-generation immunology platform was on track to more than replace Humira's peak revenues by 2027.
AbbVie acquired Pharmacyclics to secure its 50 percent share of Imbruvica (ibrutinib), the first approved BTK inhibitor for chronic lymphocytic leukemia and other B-cell malignancies. The acquisition provided AbbVie with an immediately revenue-generating oncology asset that diversified the company's revenue base away from pure Humira dependence. At $21 billion, the acquisition was the largest pharmaceutical deal of 2015 and demonstrated AbbVie's willingness to pay full prices for proven commercial assets.
AbbVie acquired Allergan to add Botox, Juvederm, and a diversified portfolio of medical aesthetics products that would generate revenue streams structurally independent of pharmaceutical patent cycles. The deal also added Allergan's prescription pharmaceutical assets including Vraylar for schizophrenia and several women's health products. Management framed the acquisition as accelerating AbbVie's revenue diversification while providing near-term accretive earnings given Allergan's existing profitability.
AbbVie acquired ImmunoGen to obtain Elahere (mirvetuximab soravtansine), the first FDA-approved antibody-drug conjugate for platinum-resistant ovarian cancer — a patient population with historically poor outcomes and limited treatment options. The acquisition also brought ImmunoGen's proprietary ADC technology platform, which has potential applications beyond the current approved indication in additional solid tumor cancer types. AbbVie's oncology team had previously focused primarily on hematological malignancies, and the ImmunoGen acquisition represented a deliberate expansion into solid tumor oncology.
AbbVie acquired Cerevel Therapeutics to obtain emraclidine, a selective muscarinic M4 agonist in Phase 3 clinical development for schizophrenia, along with several other neuroscience pipeline assets. Emraclidine's mechanism — targeting M4 receptors rather than dopamine receptors like conventional antipsychotics — offers the potential for antipsychotic efficacy without the weight gain, sedation, and metabolic effects that limit adherence to existing schizophrenia treatments. The acquisition represented AbbVie's largest bet on neuroscience and its clearest statement that it intends to build a major presence in psychiatric and neurological disorders.
AbbVie has continued to pursue smaller bolt-on acquisitions and licensing agreements that supplement its primary pipeline areas without requiring the scale of the Allergan or ImmunoGen transactions. These smaller deals typically involve early-stage assets in immunology, neuroscience, or oncology where AbbVie's commercial and regulatory infrastructure can accelerate development timelines relative to what the originating company could achieve independently.